Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Dyslipidemia | 05/09/2025 | By Dineshwori | 225
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy